Summary

Epilepsy medicine is beginning to use targeted therapy based on genetic testing. This article discusses some of the work being performed by researchers at Epi4K — Gene Discovery in Epilepsy, a center funded by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. Epi4K researchers use the most modern genetic technologies from throughout North America, Europe, and Australia in screening >4000 patient genomes for mutations that potentially influence the risk for epilepsy [Epi4K Consortium. Epilepsia 2012].